tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Archive for 'News Features'

PharmaCyte Biotech Moves Closer to Filing IND with Naming of Comparator Arm for Upcoming Clinical Trial and Discusses Pivotal Trial Opportunity

PharmaCyte Biotech Moves Closer to Filing IND with Naming of Comparator Arm for Upcoming Clinical Trial and Discusses Pivotal Trial Opportunity

LAGUNA HILLS, Calif., Feb. 13, 2017 — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today discussed the comparator arm for its upcoming clinical trial and provided additional clarification on its recent pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding its upcoming clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).

In the company’s upcoming trial, the comparator arm that ...

Read More →
0

Facebook Adds SPYR’s Pocket Starships to New Gameroom Platform

Facebook Adds SPYR’s Pocket Starships to New Gameroom Platform

DENVER February 8, 2017 — SPYR, INC. (OTCQB: SPYR), a holding company with wholly owned subsidiaries in both the mobile game & app development and publishing industry, today announced that its flagship game, Pocket Starships, is among the first games that can be played in Facebook’s new Gameroom, now available in beta, for Windows PC gamers (https://www.facebook.com/gameroom).

Pocket Starships is a popular mobile game that is one of the few titles that offers real-time, cross platform play allowing both PC and ...

Read More →
0

SPYR Updates Shareholders on Plans and Objectives for 2017

SPYR Updates Shareholders on Plans and Objectives for 2017

DENVER, February 2017 — SPYR, INC. (OTCQB: SPYR), a holding company with wholly owned subsidiaries in both the mobile game & app development and publishing industry, and in the restaurant industry, today provides its shareholders with an update on its plans and objectives for the year 2017.

SPYR’s overarching goal for 2017 and beyond is to become a premier, diversified mobile games publisher, deriving revenue from games in various genres and appealing to multiple demographics.

Pocket Starships

SPYR’s main focus in 2016 ...

Read More →
0

PharmaCyte Biotech Secures Funding Opportunity for Pancreatic Cancer Clinical Trial

PharmaCyte Biotech Secures Funding Opportunity for Pancreatic Cancer Clinical Trial

Written by Ι Stock Market Media — December 12, 2016

All of the pieces are starting to fall into place for PharmaCyte Biotech (OTCQB: PMCB) and its upcoming human clinical trial in advanced pancreatic cancer. Just one week after the U.S. Food and Drug Administration (FDA) granted the biotech a pre-IND (Investigational New Drug) meeting to discuss the company’s clinical trial, PharmaCyte qualified to use its multi-million dollar “at-the-market” funding arrangement with Chardan Capital in order to enroll every single patient into its ...

Read More →
0

PharmaCyte Biotech Discusses Upcoming Clinical Trial in Pancreatic Cancer with First Principle Investigator

PharmaCyte Biotech Discusses Upcoming Clinical Trial in Pancreatic Cancer with First Principle Investigator

LAGUNA HILLS, Calif., Dec. 07, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, released today the first article in a series of Q&A articles that will be conducted with some of the key team members of PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC). PharmaCyte’s first Q&A article is with Dr. Matthias Löhr of the famed ...

Read More →
0

PharmaCyte Biotech Moves Closer to Enrolling Patients in Pancreatic Cancer Clinical Trial

PharmaCyte Biotech Moves Closer to Enrolling Patients in Pancreatic Cancer Clinical Trial

Written by Ι Stock Market Media — December 1, 2016

Company Aiming to Produce 6-Month Breakthrough Data

PharmaCyte Biotech (OTCQB: PMCB) is now one step closer to enrolling patients in a pivotal clinic trial in advanced, inoperable pancreatic cancer after the FDA granted its request for a pre-IND (Investigational New Drug) meeting. A host of oncologists, clinicians and scientists that represent PharmaCyte will now sit down with the U.S. regulatory agency to gain valuable insight that will assist them in filing an ...

Read More →
0
Page 1 of 24 12345...»
ContactUs.com